share_log

Credit Suisse Maintains Outperform on Pear Therapeutics, Lowers Price Target to $7

Benzinga Real-time News ·  Nov 15, 2022 22:02

Credit Suisse analyst Judah Frommer maintains Pear Therapeutics (NASDAQ:PEAR) with a Outperform and lowers the price target from $9 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment